register

News & Trends - MedTech & Diagnostics

Scaling point-of-care test to combat antimicrobial resistance in ANZ

Health Industry Hub | July 8, 2024 |

Antimicrobial resistance (AMR) stands as a critical global threat to public health, primarily driven by the misuse and overuse of antimicrobials, and the development of drug-resistant pathogens. Lumos Diagnostics has taken a significant step in combatting this issue by securing an agreement with Regional Health Care Group (RHCG) in Australia and New Zealand, to distribute their FebriDx point-of-care test.

This test effectively distinguishes between viral and bacterial acute respiratory infections, aiding healthcare professionals in making rapid and accurate treatment decisions.

The collaboration marks an expansion of FebriDx’s reach through Henry Schein’s extensive Medical business network, now encompassing Australia and New Zealand. RHCG, a pivotal arm of Henry Schein, the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, will spearhead the distribution efforts.

Mike Covey, Vice President of Henry Schein for the APAC Region and Managing Director in Australia, stated “At Henry Schein, our goal is to help health care professionals enhance efficiencies through practice care so they can focus on delivering quality patient care. We are therefore delighted to expand our distribution of FebriDx beyond Portugal, Spain, the Netherlands, the United Kingdom, and the United States to now include Australia and New Zealand.”

FebriDx delivers results within 10 minutes from a simple fingerstick blood sample, facilitating swift and accurate management of infectious patients across Primary Care, Urgent Care, Emergency Departments, Paediatric facilities, and other outpatient settings. RHCG has already commenced sales and marketing initiatives to introduce FebriDx across ANZ.

“It is great to see the increased interest in our FebriDx test from one of the world’s largest distributors of healthcare and medical products,” said Doug Ward, CEO of Lumos Diagnostics.

“Henry Schein has been a terrific  and  supportive  partner  for  Lumos  across  Europe.  With  our  recent  U.S.  launch  and  the  growing commercial  interest  in  FebriDx,  we  are  now  preparing  production  of  FebriDx  to  meet  the  anticipated growing  demand  for  the  product,  to  support our  customers.  It  is very exciting  to  have  Henry  Schein  as part  of  this  strategy  with  their  expanded  distribution  coverage  for  FebriDx  in  the  Australian  and  New Zealand markets.”  

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the ONLY one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The exclusive leadership and influencer podcasts and vodcasts add huge value to our breaking news coverage. The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - Pharmaceuticals

Federal court dismisses Arrotex dispute against Health Minister

Federal court dismisses Arrotex dispute against Health Minister

Health Industry Hub | July 12, 2024 |

Pharma News: The Federal Court has ruled against Arrotex Pharmaceuticals in their bid to challenge the Minister for Health and […]

More


News & Trends - Pharmaceuticals

Largest diabetes study reveals major benefits of dual therapy with SGLT2 inhibitors and GLP1 receptor agonists

Largest diabetes study reveals major benefits of SGLT2 inhibitors and GLP1 receptor agonists dual therapy

Health Industry Hub | July 12, 2024 |

Pharma News: Combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to […]

More


News & Trends - Pharmaceuticals

Queensland opens first regional CAR T-cell treatment centre

Queensland launches first regional CAR T-cell treatment centre

Health Industry Hub | July 12, 2024 |

Pharma News: Gilead Sciences and Lymphoma Australia have welcomed the opening of Australia’s first regional CAR T-cell treatment centre at […]

More


News & Trends - Pharmaceuticals

Government inaction leaves essential medicine shortages unresolved

Government inaction leaves essential medicine shortages unresolved

Health Industry Hub | July 12, 2024 |

Pharma News: Over the past 12 months, at least six essential medications and products have been withdrawn from the Australian […]

More


This content is copyright protected. Please subscribe to gain access.